Ovid Therapeutics Inc. (OVID)

NCM – Цена в реальном времени. Валюта: USD

2.87

+0.08 (2.87%)

При закрытии: May 12, 2026, 4:00 PM EDT

2.85

-0.02 (-0.70%)

После закрытия: May 12, 2026, 7:55 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Ovid Therapeutics Inc. (OVID)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Ovid Therapeutics Inc. (OVID)

Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript

Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14

Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding

Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript

Here's Why Ovid Therapeutics Stock Popped Higher Today

Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally

Видео

No Data

Пресс-релизы

Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

Ovid Therapeutics Announces Pricing of $60 Million Private Placement

Search stocks

Ovid Therapeutics Inc. (OVID)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Ovid Therapeutics Inc. (OVID)

Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript

Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14

Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding

Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript

Here's Why Ovid Therapeutics Stock Popped Higher Today

Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally

Видео

No Data

Пресс-релизы

Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

Ovid Therapeutics Announces Pricing of $60 Million Private Placement